Number Needed to Treat. End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular.

Slides:



Advertisements
Similar presentations
Basic statistics.
Advertisements

Acute MI treatment Roger Suss MD CCFP(EM) Lecturer Dept of Family Medicine University of Manitoba.
Reporting drugs and treatments Thomas Abraham JMSC 6090.
Reporting drugs and treatments Thomas Abraham. What we will learn today The difference between absolute and relative risk reduction A basic way to interpret.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Viral Myocarditis.
Trial profile Fox K et al. Lancet 2008;372:
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
Measures of Effect: An Introduction Epidemiology Supercourse Astana, July 2012 Philip la Fleur, RPh MSc(Epidem) Deputy Director, Center for Life Sciences.
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Grinols and Mustard Impact of a casino opening on crime rates Concern: casinos are not random – opened in struggling areas Data at county/year level –
Chest Pain and Cardiac Emergencies Chest Pain and Cardiac Emergencies WelcomeChest PainCertaintySimulation.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial)
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
analysis from the SHIFT study
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
Glucose – Insulin – Potassium Study in Patients with ST Elevation Myocardial Infarction without Signs of Heart Failure Presented at American College of.
Perspective on COMMIT/CCS-2 Trial of Metoprolol in STEMI Christopher Cannon, M.D. Brigham and Women’s Hospital Boston, MA.
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
The Bahrain Branch of the UK Cochrane Centre In Collaboration with Reyada Training & Management Consultancy, Dubai-UAE Cochrane Collaboration and Systematic.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Myocardial infarction My objectives are: Define MI or heart attack Identify people at risk Know pathophysiology of MI Know the sign & symptom Learn the.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
9-1-1 COORDINATION WORKGROUP Samar Muzaffar, MD MPH.
Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.
How to Analyze Therapy in the Medical Literature (part 2)
Measures of Association Professor Mobeen Iqbal Shifa College of Medicine.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Literature Appraisal Effectiveness of Therapy. Measures of treatment effect Statistical significance Odds ratio Relative risk Absolute risk reduction.
Therapeutics: Finding a “Cure” Why Assess Therapy Articles? Evidence-based medicine Starting point for treatment decisions Apply evidence to your patients.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
Does early beta-blockade decrease mortality in STEMI?
The Health Roundtable Saving heart muscle by reducing delays to getting patients to the overnight regional catheter lab Presenter: Debby Hailstone Middlemore.
A Simple Method for Evaluating the Clinical Literature “PP-ICONS” approach Based on Robert J. Flaherty - Family Practice Management – 5/2004.
Risks & Odds Professor Kate O’Donnell. When talking about the chance of something happening, e.g. death, hip fracture, we can talk about: risk and relative.
Atypical Presentations Patients older than 75: frequently no chest pain ECG in evolution (nonspecific ECG changes) Diabetic patients: commonly no chest.
Secondary prevention of a Recurrent ACS; Results from the 2004 & 2006 ACSIS Survey Perl L, Behar S, Schwartz R, Mosseri M Meir Hospital and Sheba Tel Hashomer,
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Acute Myocardial Infarction February 8, 2006.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.
Article Title Resident Name, MD SVCH6/13/2016 Journal Club.
Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure Philippe Gabriel.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Association of Guideline-Based Admission Treatments.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
All-cause mortality by treatment group
Systolic Blood Pressure Intervention Trial (SPRINT)
Chapter 28 Management of Patients With Coronary Vascular Disorders
Baseline characteristics of patients
European Heart Association Journal 2007 April
Nat. Rev. Cardiol. doi: /nrcardio
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Baseline Characteristics by Baseline N-BNP Level
Flow Diagram of the Trial Selection Process
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Basic statistics.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Number Needed to Treat

End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular condition Absolute Risk Reduction is the risk difference between the control group and the experimental group Absolute Risk Reduction is the risk difference between the control group and the experimental group

End Points Number Needed to Treat (NNT) is the number of patients who must receive an intervention of therapy during a specific period of time to prevent one adverse outcome or produce one positive outcome Number Needed to Treat (NNT) is the number of patients who must receive an intervention of therapy during a specific period of time to prevent one adverse outcome or produce one positive outcome NNT is inversely related to the absolute risk reduction NNT is inversely related to the absolute risk reduction NNT incorporates the influence of the baseline risk NNT incorporates the influence of the baseline risk Can be expressed in whole numbers Can be expressed in whole numbers

Baseline Risk The absolute risk associated with a particular condition The absolute risk associated with a particular condition Killip Class Mortality in 30 days Killip Class Mortality in 30 days Class I 6% Class II 17% Class III 38% Class IV 81%

Risk After Treatment New risk after receiving experimental treatment New risk after receiving experimental treatment Lytics (experimental treatment) reduces risk by 12% Lytics (experimental treatment) reduces risk by 12% 81%X.12 = %-10%= 71%

Absolute Risk Reduction Risk Difference between your control group and your experimental group Risk Difference between your control group and your experimental group Baseline Risk - Risk after Treatment = ARR or risk difference 81%-71% = 10%

Tale of Two Heart Attacks Patient A Patient A September M with no PMH presents to ED in rural Robeson County with ECG findings suggesting inferior myocardial infarction. No signs of heart failure and is in NSR pulse 90. September M with no PMH presents to ED in rural Robeson County with ECG findings suggesting inferior myocardial infarction. No signs of heart failure and is in NSR pulse 90. Patient B Patient B September M with no PMH presents to ED in rural Robeson County with ECG findings suggesting anterior myocardial infarction with evidence of pulmonary edema

What do you do? A. Go straight to cath lab A. Go straight to cath lab B. Give lytics B. Give lytics C. Heparin and CCU C. Heparin and CCU D. floor with telemetry D. floor with telemetry

Review Patient A Patient A Killip Class I- no signs of heart failure 6% mortality in 30 days Patient B Patient B Killip Class III- frank pulmonary edema 38% mortality in 30 days tPA tPA reduces mortality risk by 12% Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience of 250 patients. Am J Cardiol 1967; 20: Treatment of myocardial infarction in a coronary care unit: a two year experience of 250 patients.

Handout Exercise

End Point #1 Number Needed to Treat (NNT) is the number of patients who must receive an intervention of therapy during a specific period of time to prevent one adverse outcome or produce one positive outcome Number Needed to Treat (NNT) is the number of patients who must receive an intervention of therapy during a specific period of time to prevent one adverse outcome or produce one positive outcome

Killip Class I Killip Class I For all Killip Class I pts we would treat 100 pts with lytics to prevent 1 death in 30 days Killip Class II Killip Class II For all Killip Class II pts we would treat 50 pts with lytics to prevent 1 death in 30 days Killip Class III Killip Class III For all Killip Class III pts we would treat 20 pts with lytics to prevent 1 death in 30 days Killips Class IV Killips Class IV For all patient B’s presenting to this hospital we would have to treat 10 pts with lytics to prevent 1 death in 30 days NNT

End Point #2 NNT is inversely related to the absolute risk reduction NNT is inversely related to the absolute risk reduction 100/ARR or Risk Difference = NNT Control tPa Control tPa Patient B 38%33% ARR= 38%-33%= 5% NNT= 100%/5%= 20

End Point #3 NNT incorporates the influence of the baseline risk NNT incorporates the influence of the baseline risk Baseline Risks NNT Patient A 6% (I)100 17% (II) 50 17% (II) 50 Patient B38% (III)20 81% (IV)10 The higher the baseline risk, the higher the ARR, the lower the NNT.